Oct 21, 2021

Featuring perspectives from Drs Jeff Sharman, Mitchell Smith and Philip Thompson, including the following topics:

• Treatment of CLL in 2021
  • Introduction (0:00)
  • First-line therapy for a younger and fit patient with CLL (11:52)
  • Case: A man in his mid-60s with IGHV-unmutated CLL — Mitchell R Smith, MD, PhD (16:20)
  • Case: A man in his mid-30s with IGHV-unmutated CLL — Philip A Thompson, MD, BS (20:24)
  • Case: A woman in her late 60s with IGHV-mutated, trisomy 12, TP53 wild-type CLL — Jeff Sharman, MD (25:11)
  • First-line therapy for older and frail patients with CLL (26:55)
  • Case: A man in his early 70s with IGHV-unmutated CLL — Dr Thompson (31:04)
  • First-line therapy for patients with high-risk CLL (33:37)
  • Choice of Bruton tyrosine kinase (BTK) inhibitor for the treatment of CLL (36:02)
  • Prevention and management of COVID-19 in patients with CLL (43:21)
• Future Treatment of CLL
  • Future role of BTK inhibitors combined with venetoclax in the management of CLL (48:33)
  • Future role of pirtobrutinib (LOXO-305) in the management of CLL (52:22)
  • Case: A woman in her late 60s with multiregimen-relapsed CLL — Dr Sharman (55:10)
  • Case: A woman in her mid-50s with multiregimen-relapsed CLL — Dr Thompson (57:32)

CME information and select publications